Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells

abstract:
Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells

 Highlights

•

Systematic drug and molecular profiling discovers new therapies in ovarian cancer.

•

AGCT cells show selective sensitivity to a TKI dasatinib and mTOR inhibitors.

•

Dasatinib or mTOR inhibitors synergize with paclitaxel in AGCT cells. (ovarian granulosa cell tumor)

Methods

The responses of three primary and four recurrent AGCTs to 230 anticancer compounds were screened in vitro using a systematic drug sensitivity and resistance testing (DSRT) platform, coupled with mRNA sequencing. The responses of the AGCTs were compared with those of human granulosa luteal cells and bone marrow mononuclear cells.